Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market.
Norstella now has more than 1,500 employees across its five brands: Evaluate, MMIT, Panalgo, The Dedham Group, and Citeline.
“We believe that patient access starts with identifying unmet needs and doesn’t end until a patient has a therapy in hand,” commented Mike Gallup, CEO of Norstella.
“As the industry moves toward highly targeted therapies focused on smaller patient populations, our clients need solutions that provide actionable answers to critical business questions to help bring drugs to market quicker – ultimately helping patients receive treatment sooner.”
As a combined organisation, Norstella aspires to identify unmet clinical needs early, construct clinical trials with informed endpoints that support downstream reimbursement decisions, and precisely identify eligible patients for clinical trials.
